Clinical Research Directory
Browse clinical research sites, groups, and studies.
Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Summary
This study evaluates the capacity of the NovaGray RILA Breast® test to predict the toxicity linked to radiotherapy and the impact of implant breast reconstruction.
Official title: Prospective Evaluation of a Predictive Toxicity Test Post Radiotherapy After Mastectomy With Immediate Implant Reconstruction
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
250
Start Date
2020-12-11
Completion Date
2027-06
Last Updated
2024-11-05
Healthy Volunteers
No
Interventions
NovaGray RILA Breast® test
The test consists of a blood sample of 2x4 mL. This test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of neoadjuvant chemotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of adjuvant chemotherapy.
Locations (9)
Centre Georges François Leclerc
Dijon, France
Centre Oscar Lambret
Lille, France
Centre Léon Bérard
Lyon, France
Institut Paoli Calmette
Marseille, France
Institut du Cancer de Montpellier
Montpellier, France
centre Antoine Lacassagne
Nice, France
Hôpital Tenon
Paris, France
Institut de Cancérologie de l'Ouest
Saint-Herblain, France
Institut Claudius Regaud
Toulouse, France